The Foundation has helped to organize, and is a General Partner of, the Venture Fund, a $350 million fund focused on pre-clinical, Phase I, Phase II, and Phase III investments. The Fund executed a first close by June 2018, and a second close by early 2019.
The Fund invests primarily within the United States, but have a small allocation for foreign investments.
Sector interests include drugs, medical devices, and novel approaches. The firm is also open to funding technologies designed to accelerate cancer research and drug development, such as novel drug discovery tools or algorithms. The firm finances projects from the early discovery stage through to Phase III clinical trials. The foundation considers projects in any type of cancer.
If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.
Leave a Reply